Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Vitamin D  COVID-19 treatment studies for Vitamin D  C19 studies: Vitamin D  Vitamin D   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent: 
0 0.5 1 1.5 2+ Mortality 93% Improvement Relative Risk Ventilation 50% ICU admission 50% NIV 48% c19early.org/d Fiore et al. Vitamin D for COVID-19 LATE TREATMENT Favors vitamin D Favors control
Effectiveness of Vitamin D Supplements among Patients Hospitalized for COVID-19: Results from a Monocentric Matched-Cohort Study
Fiore et al., Healthcare, doi:10.3390/healthcare10050956
22 May 2022    Source   PDF   Share   Tweet
Retrospective 116 patients with D levels < 30ng/mL, 58 treated with vitamin D 100,000IU daily for two days, and 58 matched controls, showing significantly lower mortality with treatment.
risk of death, 92.7% lower, RR 0.07, p = 0.01, treatment 3 of 58 (5.2%), control 11 of 58 (19.0%), NNT 7.2, adjusted per study, odds ratio converted to relative risk, multivariable.
risk of mechanical ventilation, 50.0% lower, RR 0.50, p = 0.36, treatment 4 of 58 (6.9%), control 8 of 58 (13.8%), NNT 14.
risk of ICU admission, 50.0% lower, RR 0.50, p = 0.36, treatment 4 of 58 (6.9%), control 8 of 58 (13.8%), NNT 14.
NIV, 47.8% lower, RR 0.52, p = 0.04, treatment 12 of 58 (20.7%), control 23 of 58 (39.7%), NNT 5.3.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Fiore et al., 22 May 2022, retrospective, matched cohort, Italy, peer-reviewed, mean age 62.5, 10 authors, dosage 100,000IU days 1-2.
Contact: vitofiore30010516@gmail.com (corresponding author), andreadevitoaho@gmail.com, paola.bagella@tiscali.it, princic_e@hotmail.com, annaanto82@gmail.com, dentilucia@outlook.it, giordano@uniss.it, babuder@uniss.it, imaida@uniss.it, agfois@uniss.it.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperVitamin DAll
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit